This study demonstrates that cilofexor improves cholestatic liver injury and decreases hepatic fibrosis, a key driver of liver failure in PSC, and to a certain extent hepatic inflammation, in the Mdr2-/- mouse model of sclerosing cholangitis. This evidence concerns the gene ABCB4 and pancreatic serous cystadenoma.